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Subclinical Hypothyroidism and Risk for Incident Ischemic
Stroke Among Postmenopausal Women
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Robin Schectman,5 Gerardo Heiss,4 Jennifer G. Robinson,6 and Katherine E. Hartmann1,7
Background: Subclinical hypothyroidism (SCH) is postulated to increase stroke risk via atherogenic changes
associated with abnormal thyroid function. However, the direct relationship of SCH with subsequent stroke is
poorly studied.
Methods: In this nested case–cohort study, we prospectively evaluated the association between any SCH and
severity of SCH in relation to incident ischemic stroke risk among postmenopausal women in the Women’s Health
Initiative Observational Study. Trained Women’s Health Initiative staff, masked to thyroid status, adjudicated
stroke cases. We assessed thyroid function using baseline blood specimens. Women with normal free thyrox-
ine levels and thyrotropin (TSH) levels ‡ 4.69 mU/L were considered to have SCH. Primary analysis included
639 ischemic stroke cases and 2927 randomly selected subcohort members with an average of seven years of
follow-up.
Results: The multivariable adjusted hazard ratios (HR) from weighted Cox models were 1.06 (95% confidence
interval [CI]: 0.77, 1.46) and 0.99 (95% CI: 0.67, 1.47) for women with any SCH and with mild SCH (TSH 4.69
to 6.99 mU/L), when compared with women with normal thyroid function. The HR for moderate/severe SCH
(TSH ‡ 7.00 mU/L) was modestly elevated (HR: 1.22; 95% CI: 0.73, 2.05).
Conclusions: We found no evidence to suggest an association between SCH and ischemic stroke among healthy
postmenopausal women.
Introduction
Subclinical hypothyroidism (SCH) is a condition inwhich thyroid hormone levels are within the normal
range but thyrotropin (TSH) levels are elevated, and may
be indicative of deteriorating thyroid function (1). This
pre-clinical condition is more common with advancing age
and may affect 10–15% of postmenopausal women (2–4).
Screening for SCH has been a persistent area of discussion for
nearly two decades. Whether screening for SCH is warranted,
for which population, and at what age, remain major points of
contention. The United States Preventive Services Task
Force and the Institute of Medicine Medicare reports con-
cluded there is insufficient evidence to endorse screening or
treatment of SCH in part because of scant scientific literature
specifically focused on the potential value of screening for or
treatment of SCH (5,6). No clinical trials have been com-
pleted to determine whether identification and treatment of
SCH prevents cardiovascular outcomes.
Indirect evidence for or against screening can be drawn
from observational studies that evaluate the relationship
between SCH and cardiovascular diseases. SCH has been
reported to be associated with the grouping of conditions
loosely termed coronary heart disease (7,8), ischemic heart
disease (9), or cardiovascular disease (10), with defini-
tions including but not limited to myocardial infarction
(MI), angina, heart failure, stroke, and other cerebrovas-
cular conditions. However, evidence for an association is
not consistent and ranges from strong effects (two-fold
increased risk) to null (8). Discrepancies likely arise from
the heterogeneity of the composite outcomes, varying
follow-up time, and differing population characteristics
such as age range, sex, and varied cardiovascular disease
status at baseline. Mixed findings extend to the relationship
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between SCH and intermediate endpoints such as athero-
sclerotic disease and lipid profiles (11,12).
Because the goals of screening for primary prevention are
to identify individuals in a preclinical phase in order to reduce
morbidity and mortality, motivation to screen for SCH must
include specific outcomes that could be prevented if SCH
were identified and treated. Using Women’s Health Initiative
Observational Study (WHI-OS) data comparable to that
for this investigation, we have previously reported that an
association of SCH with incident myocardial infarction is
not supported by prospective data in postmenopausal women
(13). The WHI-OS (14) is a well-characterized cohort of
ethnically diverse postmenopausal women with biological
samples available at baseline, a high follow-up rate, and a
rigorous adjudication process for outcomes.
To round out examination of the association of SCH with
cardiovascular disease by investigation of specific outcomes,
our research team focused on whether there is evidence to
support a link between SCH and incident ischemic stroke
among healthy postmenopausal women, a population with
high prevalence of SCH. Only two other studies, which were
underpowered, have reported on the association between
SCH and stroke (15,16). Our investigation improves on these
previous studies. We employed an efficient nested case–
cohort study design to reach sufficient power in the largest
prospective study to date that can examine for main effects as




Women in this study were participants in the WHI-OS, a
cohort of postmenopausal women between 50 and 79 years of
age enrolled at 40 clinical centers across the United States
between October 1993 and December 1998 (17). Inclusion/
exclusion criteria for this ancillary analysis have been de-
tailed previously (13). Briefly, from 93,676 women in the
WHI-OS, women with anticipated residence in the local area
for at least three years with baseline serum available in the
specimen bank were eligible for inclusion. Exclusion criteria
were self-reported history of current or previous thyroid disease,
use of medications that may alter thyroid hormones, history of
MI or stroke, history of coronary artery bypass grafting or ca-
rotid endarterectomy, and missing race/ethnicity data.
Ischemic stroke cases
WHI investigators conducted ascertainment of incident
ischemic stroke cases every 12 months via review of self-
reported annual medical follow-up updates (18). Ischemic
stroke was defined as the rapid onset of persistent neu-
rologic deficit lasting for 24 hours or more due to an ob-
struction, fatal or nonfatal, or detection of lesion through
computed tomography or magnetic resonance imaging scan.
Fatal and nonfatal locally adjudicated ischemic stroke cases
through December 15, 2004 that were additionally confirmed
by central adjudication by trained neurologists were consid-
ered for inclusion. Adjudicators were masked to participants’
thyroid status. Reports of transient ischemic attacks and
hemorrhagic strokes were not considered in this study. A total
of 1050 cases were identified. After applying our inclusion/
exclusion criteria, 675 cases were eligible for this analysis.
Figure 1 provides details of exclusions. Because our goal was
to examine the effects of SCH at baseline on future ischemic
stroke risk, we further excluded observations that our labo-
ratory analyses identified as having overt thyroid disease
(n = 9) or subclinical hyperthyroidism (n = 16). Participants
who had negative follow-up time (n = 6) or for whom labo-
ratory measures were unavailable (n = 5) were also excluded.
A total of 639 incident ischemic stroke cases were included in
the primary unadjusted analysis.
Comparison subcohort
By design, the subcohort for this study was generated to
serve as a common comparison group for two separate ana-
lyses— one that evaluates SCH and risk for MI (13) and the
present analysis. The same inclusion/exclusion criteria used
for selection of MI and stroke cases were also applied to the
entire WHI-OS cohort. We used random sampling and den-
sity matching within five-year age strata to match the age
distribution of the 800 MI and 675 stroke cases, identifying
3200 members for the comparison subcohort (Fig. 1). We
obtained stored specimens for the subcohort and conducted
the same laboratory analyses as for case groups; observations
in the subcohort with subclinical hyperthyroidism, with overt
thyroid disease, and with no laboratory measures were ex-
cluded. After exclusions, the subcohort consisted of 2927
observations available for primary unadjusted analysis.
Thyroid hormone measurement
Laboratory procedures for thyroid measurements have
been described in detail previously (13). Briefly, specimens
were analyzed between March 2005 and December 2006.
FIG. 1. Schema representing the selection process for is-
chemic stroke cases and subcohort from the Women’s
Health Initiative Observational Study (WHI-OS). Adapted
with permission from LeGrys et al. (13).
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Laboratory personnel were blind to participant characteristics
including stroke or MI status. TSH was measured using a
chemiluminescent immunometric assay with a detection
range from 0.01 to 100 mU/L. TSH values between 0.46
and 4.68 mU/L were considered the normal reference range
(euthyroid). Specimens with TSH values above or below
the normal reference range were tested for free thyroxine
(FT4) and thyroid peroxidase antibodies (TPOAb). FT4
was measured using a competitive chemiluminescent assay
with a detection range of 0.1–12.0 ng/dL. FT4 concentrations
within 0.70–1.85 ng/dL were the normal reference range.
TPOAb was measured using a solid-phase, sequential chemi-
luminescent immunometric assay with a detection range of
10–1000 IU/mL. Specimens with TPOAb concentrations
‡ 35 IU/mL were considered to be TPOAb positive. All sam-
ples included in the study met quality control criteria. Samples
with TSH values ‡ 4.69 mU/L and normal FT4 levels were
classified as indicating SCH.
Statistical analyses
The sampling strategy of a case–cohort design allows re-
sampling of cases into the subcohort portion of the popula-
tion. Thus, pseudo-likelihood based methods must be used
to account for the non-independent score contributions. We
used weighted Cox-proportional hazards models as proposed
by Barlow and colleagues (19) along with jackknife esti-
mated robust standard errors (20) to appropriately account for
the non-independence and provide reliable estimates of the
hazard ratio (HR) and variance. We report unadjusted and
multivariable adjusted associations between SCH and stroke.
Candidate covariates were chosen a priori as either potential
confounders or established risk factors for stroke. These in-
cluded age, race/ethnicity, WHI site, years since menopause,
gravidity, parity, hypertension, current diabetes, hormone
therapy (HT), smoking history, alcohol consumption, phys-
ical activity, body mass index, and waist-to-hip ratio.
We developed a parsimonious model using directed acy-
clic graphs to include only confounders in the assessment of
any SCH and its relationship to stroke. We did not impute
missing data and report hazard ratios based on complete-case
analysis. There were 626 cases and 2843 subcohort mem-
bers available in the primary parsimonious model examining
any SCH and stroke. Variables included in the parsimonious
models were age, ethnicity, smoking status, HT use, gra-
vidity, and alcohol consumption. All subsequent models were
adjusted for these variables. Additional adjustment for risk
factors such as diabetes status, physical activity, waist-to-hip
ratio, and/or body mass index in a fully adjusted model
changed effect estimates negligibly. In addition to examining
the association between any SCH and stroke, we conducted
separate analyses by stratum of SCH severity, restricted to
exposed individuals who had mild SCH (TSH 4.69 to
6.99 mU/L), moderate/severe SCH (TSH ‡ 7.00 mU/L), and
individuals who had moderate/severe SCH and were TPOAb-
positive. All were compared to women with normal thyroid
function. We used the likelihood ratio test to formally eval-
uate effect modification of the association between severities
of SCH and stroke by age, smoking status, waist-to-hip ratio,
ethnicity, alcohol consumption, gravidity, and HT use. We
tested the proportional hazards (PH) assumption by visual
inspection of log–log survival curves and by including an
interaction term for natural log–transformed follow-up time
and the SCH variables in the Cox-models. We detected no
gross violations of the PH assumption.
We conducted several sensitivity analyses. First, we re-
examined the association between SCH and stroke by re-
moving individuals with potentially impending overt thyroid
disease (TSH ‡ 20 mU/L). Second, to facilitate comparisons
with other studies which report varying thresholds for SCH
(8,21,22), we reanalyzed data by changing the TSH threshold
for SCH, decreasing it to 4.50 mU/L and increasing it to
5.00 mU/L. Third, to examine the association between SCH
and stroke without the influence of intercurrent diagnosis and
treatment of thyroid disease, we restricted our analysis to
women who had follow-up information on these factors in
year three, and then excluded women who reported using
thyroid medications. Data compilation and bivariate analyses
were done in STATA 12 (College Station, TX). Weighted
Cox-PH models were generated using SAS 9.3 (Cary, NC).
This study was reviewed and determined to be exempt from
further review by the Institutional Review Board at the
University of North Carolina, Chapel Hill, and was approved
by the Institutional Review Board at Vanderbilt University.
Results
The mean age of the 3566 women included in this case–
cohort analysis was 67.5 years, and the majority self-identified
as Caucasian/white (83.9%). Baseline thyroid measures indi-
cated 280 women (7.8%) had SCH (TSH ‡ 4.69 mU/L), the
majority (68.2%) of whom had mild SCH (TSH 4.69 to
6.99 mU/L), and the remaining had moderate/severe SCH
(TSH ‡ 7.00 mU/L). Increasing age was positively associated
with SCH, and whites were more likely to have SCH than other
races/ethnicities. At baseline, compared with participants in
the subcohort, stroke cases were more likely to be older,
heavier, and more likely to have had 5 or more pregnancies.
Stroke cases were also more likely to be current smokers, and
have diabetes and hypertension. Stroke cases were less likely
to consume alcohol and less likely to be physically active,
although the latter was not statistically significant (Table 1).
Baseline characteristics of the randomly sampled subcohort
are very similar to the entire WHI-OS cohort (17).
Cumulative stroke incidence curves for euthyroid women,
women with mild SCH, and women with moderate/severe
SCH during the average 7-year follow-up period are shown
in Fig. 2. Risk for stroke among women with any SCH at
baseline was not appreciably different than for women with
normal thyroid function at baseline (Table 2); the corre-
sponding multivariable adjusted hazard ratio was 1.06 [95%
confidence interval (CI): 0.77, 1.46]. Compared with women
with normal thyroid function, HRs for women with mild SCH
and moderate/severe SCH were 0.99 [CI: 0.67, 1.47] and 1.22
[CI: 0.73, 2.05], respectively. Women who had moderate/
severe SCH and were also TPOAb positive had a hazard ratio
of 0.83 [CI: 0.42, 1.64] (Table 3).
We found no meaningful interactions with age, smoking
status, ethnicity, alcohol consumption, or gravidity (Sup-
plementary Table S1; Supplementary Data are available
online at www.liebertpub.com/thy). There was marginal
evidence for effect modification by HT status on the rela-
tionship of moderate SCH and stroke risk ( p = 0.07), with
higher risk associated with moderate SCH for current (HR:
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1.78; [CI: 0.56, 5.61]) and past (HR: 2.37; [CI: 0.52, 10.85])
HT users than for women who reported never (HR: 0.69;
[CI: 0.30, 1.60]) using HT.
In our first sensitivity analysis, excluding women who had
impending overt hypothyroidism (TSH ‡ 20 mU/L) yielded
similar results as those for women with any SCH (HR: 1.05;
[CI: 0.76, 1.45]), and those with moderate/severe SCH (HR:
1.19; [CI: 0.69, 2.05]). Similarly, in our second analysis,
changing the TSH threshold from 4.69 mU/L to 4.50 mU/L or
to 5.00 mU/L did not substantially change our results. Third,
among women who reported information on thyroid medi-
cation use at 3 years of follow-up, exclusion of women who
were using thyroid medications yielded similar results (HR:
0.91; [CI: 0.74, 1.13]) for any SCH.
Discussion
In this large case–cohort investigation of postmenopausal
women from the WHI-OS, we did not find evidence to sug-
gest an association between SCH at baseline and risk for
incident ischemic stroke. Compared with women with normal
thyroid function, effect estimates were only modestly elevated
for women with moderate/severe SCH (TSH ‡ 7.00 mU/mL);
however, the confidence interval included unity. Projecting
750 stroke cases, a 1:4 case–cohort ratio, and a type-1 error of
5%, a priori approximation of the minimum detectable effect
estimate was 1.43 with 90% power if prevalence of SCH was
10%, and 1.81 with 80% power if prevalence of SCH was 2%.
Post-hoc calculations based on population available for anal-
ysis (639 cases, 2927 comparison cases) demonstrated a 7.8%
SCH prevalence; with a type-1 error rate of 5%, we had 80%
power to detect an effect estimate of 1.51. Despite targeting
our investigation to a population with high prevalence of SCH
and relatively high incidence of stroke, the effect estimates we
observed for SCH were very close to the null.
Our search of the literature identified only two prospective
cohort studies (Table 3) that specifically reported on SCH and
stroke risk. They have diametrically opposed and under-
powered associations (15,16). Rodondi and colleagues re-
ported larger effect estimates for participants with moderate
SCH, defined as TSH 7.00 to 9.99 mU/L (HR: 2.16; [CI: 0.93,
5.00]; with 7 strokes) than for those with mild SCH, defined
as TSH 4.5 to 6.9 mU/L (HR: 1.13; [CI: 0.62, 2.07]; 12
strokes), during a 4-year follow-up (15). Schultz and col-
leagues reported a hazard ratio of 0.74 [CI: 0.10, 5.50] for
participants with SCH compared with euthyroid participants
with 31 SCH cases at baseline and 28 incident stroke cases
(one stroke case in the SCH group) (16). Effect estimates
from both studies lack precision, as indicated by the confi-
dence intervals. Two other studies reported the association
between SCH and incident cerebrovascular disease, includ-
ing stroke events. One observed a null effect-estimate (21),
HR of 1.01 [CI: 0.79, 1.29], and the other observed elevated
risk with an HR of 1.9 [CI: 0.5, 7.30] (22); neither performed
analyses using information about severity of SCH.
The mechanisms relating overt hypothyroidism to cardio-
vascular and cerebrovascular conditions including coronary
heart disease, MI, and stroke are well understood. Overt hy-
pothyroidism has been associated with atherogenic lipid pro-
files, diastolic hypertension, impaired endothelial function,
hyperhomocysteinemia, and increased C-reactive protein lev-
els (23–26). The mechanisms relating SCH to cerebrovascular
Table 1. Distribution of Baseline Characteristics
and Cardiovascular Risk Factors According to
Case and Subcohort Status Among 3566






(N = 2927) p-Value*
N (%) N (%)
Age at baseline (years) 0.006
50–64 116 (26.0) 950 (32.5)
65–70 208 (32.5) 862 (29.4)
71–79 265 (41.5) 1115 (38.1)
Race or ethnic group 0.126
White 543 (85.2) 2448 (83.8)
Black 62 (9.6) 242 (8.3)
Hispanic 10 (1.6) 84 (2.9)
Asian or Pacific
Islander
14 (2.2) 108 (3.7)
American Indian 4 (0.6) 15 (0.5)
Other 4 (0.6) 24 (0.8)
Waist-to-hip ratio 0.001
£ 0.80 268 (42.1) 1437 (49.4)
> 0.80–0.85 163 (25.6) 719 (24.7)
> 0.85 205 (32.3) 755 (25.9)
Physical activity level 0.081
None/mild 335 (53.0) 1389 (48.2)
Moderate 179 (28.3) 871 (30.3)
Strenuous 118 (18.7) 619 (21.5)
Smoking 0.003
Never 337 (53.0) 1528 (53.1)
Past 246 (38.7) 1204 (41.9)
Current 53 (8.3) 143 (5.0)
Alcohol 0.007
< 1 drink per week 416 (65.4) 1705 (58.7)
1–6 drinks per week 140 (22.0) 784 (27.0)
7 + drinks per week 80 (12.6) 417 (14.3)
Diabetes < 0.000
No 559 (88.7) 2777 (95.5)
Yes 71 (11.3) 131 (4.5)
Gravidity
Never pregnant 54 (8.5) 293 (10.1)
1 37 (5.8) 188 (6.5)
2–4 353 (55.7) 1737 (59.7)
5 + 190 (30.0) 691 (23.7)
Hormone use 0.592
Never 288 (45.1) 1342 (45.9)
Past 101 (15.8) 496 (17.0)
Current 250 (39.1) 1086 (37.1)
Years from menopause < 0.000
0–15 157 (27.7) 847 (31.8)
16–23 176 (31.0) 956 (35.9)
24–26 234 (41.3) 861 (32.3)
Hypertension < 0.000
Never 211 (33.2) 1549 (53.2)
Past or controlled 128 (20.1) 577 (19.8)
Current 297 (46.7) 785 (27.0)
Numbers do not always total 3566 due to missing data for
covariates.
*p-Value: calculated using the Pearson’s chi-squared test.
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Table 2. Ischemic Stroke Hazard Ratios [95% CI] in Relation to Any Subclinical Hypothyroidism,
Its Severity, and Presence of Thyroid Peroxidase Antibody Among Women from the Women’s
Health Initiative Observational Study
Thyroid condition N (case/cohort) HR [95% CI]
Unadjusteda
Euthyroid 582/2704 1.00 [Referent]
Any SCHb 57/223 1.13 [0.83–1.53]
Mildc 36/155 1.05 [0.72–1.53]
Moderate/severed 21/68 1.30 [0.79–2.15]
Moderate/severe & TPOAb positivee 11/51 0.90 [0.47–1.75]
Natural log-transformed TSH (continuous)f 639/2927 1.01 [0.99–1.04]
Unadjustedg
Euthyroid 569/2626 1.00 [Referent]
Any SCHb 57/217 1.16 [0.85–1.57]
Mildc 36/151 1.07 [0.74–1.56]
Moderate/severed 21/66 1.34 [0.81–2.22]
Moderate/severe and TPOAb positivee 11/49 0.94 [0.49–1.83]
Natural log-transformed TSH (continuous)f 626/2843 1.02 [0.99–1.04]
Multivariable adjustedh
Euthyroid 569/2626 1.00 [Referent]
Any SCHb 57/217 1.06 [0.77–1.46]
Mildc 36/151 0.99 [0.67–1.47]
Moderate/severed 21/66 1.22 [0.73–2.05]
Moderate/severe & TPOAb positivee 11/49 0.83 [0.42–1.64]
Natural log-transformed TSH (continuous)f 626/2843 1.01 [0.98–1.04]
aSample size based on entire sample.
bAny subclinical hypothyroid vs. euthyroid.
cMild subclinical hypothyroid (thyrotropin [TSH] 4.69 to 7.0 mU/L) vs. euthyroid (moderate/severe category omitted).
dModerate/severe subclinical hypothyroid (TSH ‡ 7.0 mU/L) vs. euthyroid (mild category omitted).
eModerate/severe and thyroid peroxidase antibody (TPOAb) positive vs. euthyroid (mild and TPOAb negative omitted).
fCox regression was modeled with ln(TSH) as a continuous variable; corresponding hazard ratios are for every 20% increase in TSH.
gSample size based on same observations used in the adjusted model.
hAdjusted for age, ethnicity, gravidity, smoking status, hormone therapy, and alcohol consumption; covariates measured at baseline only.
CI, 95% confidence interval; HR, hazard ratio; SCH, subclinical hypothyroidism.
FIG. 2. Nelson-Aalen cumula-
tive hazard estimates for ischemic
stroke by severity of subclinical
hypothyroidism (SCH) among wo-
men from the WHI-OS. Solid line
represents euthyroid participants;
short-dashed line represents
participants with mild subclinical
hypothyroidism; long-dashed line




(TSH) 0.46–4.68 mU/L; Mild SCH,
TSH 4.69–6.99 mU/L; Mod/Sev
SCH, TSH ‡ 7.00 mU/L.
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conditions such as stroke are less clearly understood. Studies
have shown SCH to be associated with increased carotid arte-
rial stiffness (27), elevated serum low-density-lipoprotein
cholesterol (28,29) and apolipoprotein-B (30), elevated mean
platelet volume (31), and altered low-density-lipoprotein-C
oxidizability (32); however, evidence has not been consistent
(12). In the context of vascular diseases, it is likely that the
downstream effects of overt hypothyroidism are due to reduced
thyroxine levels rather than elevated TSH, which serves as an
indicator of the dysfunction. If SCH is in fact associated with
stroke or MI, it would likely be due to similar mechanisms as
with overt hypothyroidism. Contrary to expectations, the haz-
ard ratio for individuals with moderate/severe SCH who were
also TPOAb positive was in the inverse direction in our study.
Several studies have observed improvement in cardio-
vascular outcomes associated with overt hypothyroidism and
SCH after treatment with L-thyroxine (30,33,34), although
results are inconsistent. Even though FT4 levels among pa-
tients with SCH are within ‘‘normal range,’’ there is a con-
tinuum of FT4 levels within this group, with some individuals
presenting with FT4 concentrations closer to the overt hy-
pothyroidism spectrum. This is also evident in our study; we
observed a mean decrease in FT4 levels with increasing
severity of SCH. Mean FT4 concentrations in individuals
with mild (TSH 4.69 to 6.99 mU/L), moderate (TSH 7.00 to
9.99 mU/L), and severe SCH (TSH ‡ 10.00 mU/L) were 1.03,
0.94, and 0.86 ng/dL respectively (data not shown). Thus
lower thyroxine levels in more severe forms of SCH could
diminish its inhibitory effects on collagen-induced platelet
aggregation and increase vascular resistance. Hypothesiz-
ing that SCH-mediated onset of coronary heart disease and
stroke share similar pathways, Rodondi and colleagues con-
ducted a meta-analysis of SCH and coronary heart disease and
found elevated risk in participants with severe SCH (TSH
‡ 10.00 mU/L), but not in participants with relatively milder
forms of SCH (8), a likely consequence of decreased FT4.
Similarly, McQuade and colleagues reported a lack of asso-
ciation between mild-SCH and all-cause mortality, but re-
ported statistically significant hazard ratios for those with
moderate SCH and severe SCH, all compared with euthyroid
participants (35). Additionally, studies have suggested an
inverse correlation between serum FT4 levels and athero-
sclerosis among euthyroid patients (36,37). The antagonistic
effect of estrogen use on efficacy of l-thyroxine therapy has
been documented (38). Our observation of higher effect esti-
mates for stroke in relation to moderate/severe SCH among
HT users than among those who never used HT is consistent
with the idea that FT4 may play a more active role in mediating
the relationship between SCH and cardiovascular risk than
TSH. However, evidence for this effect modification is only
suggestive ( p = 0.07) in our study and the possibility of chance
as an explanation is not to be ruled out.
A plausible reason for observing no association between
any SCH and stroke is potential misclassification of SCH
subjects over the course of the study, which could have biased
our results towards the null. We measured thyroid hormones
only at baseline and were unable to track thyroid status after
baseline except by claim. Somwaru and colleagues reported
46% of participants with mild SCH reverted from SCH to
euthyroid status over a two-year period (39). However, in the
same study as few as 10% of the participants with moderate
SCH (TSH 7.0 to 9.9 mU/L) and 7% of the participants with
severe SCH (TSH ‡ 10.0 mU/L) reverted back to euthyroid
status during the same 2-year period. Thus, in our study, error
due to misclassification in the moderate/severe group is
likely to be low. Furthermore, we are unable to assess stroke
risk by FT4 levels because only specimens above and below
the normal TSH reference range were tested for FT4. Ad-
ditionally, we did not assess stroke risk exclusively among
individuals with severe SCH due to the small number of par-
ticipants that met this criterion. It is also possible that an
average of 7 years (interquartile range: 6.0 to 8.4 years) of
follow-up was not sufficient to detect the cumulative effect of
mild SCH on stroke occurrence. Finally, lacking information
on lipid characteristics, we were not able to examine the me-
diating effects of lipids on SCH-mediated stroke occurrence. It
should however be noted that even if this information were
available and we assume that this model is correct, adjustment
for lipid characteristics would only further work to nullify any
elevated association between SCH and stroke, consequently
strengthening the current conclusion of this investigation.
Despite these drawbacks, to our knowledge, this is the
largest study (639 stroke cases) to date to have explicitly
examined SCH and risk for stroke. The size of the study
allowed us to report the marginal association between SCH
and stroke, after adjusting for potential confounders. Our
sample was also large enough to report effect estimates by
severity of SCH. Furthermore, we conducted multiple sen-
sitivity analyses, which did not appreciably change our re-
sults. Density-matched sampling of the comparison cohort
from the entire eligible WHI-OS ensured a good approxi-
mation of the risk ratio and minimized the possibility of se-
lection bias because cases and subcohort both originated from
the same base population.
In this population of postmenopausal women with no
history of cardiovascular conditions, we did not find evidence
of association between SCH and risk for incident ischemic
stroke. This was particularly true for mild SCH. In con-
junction with biological rationale, there is still reason to
speculate that individuals with more severe forms of SCH
may be at increased risk for stroke. However, given the lower
prevalence of moderate/severe SCH and the modest elevation
of stroke risk (if any) associated with it, its impact on a
population level is likely to be small and thus the utility of
screening to forestall stroke outcomes extremely low or
Table 3. Characteristics of Past Studies Reporting






Average follow-up time 5 years 4 years
% Women 58.2% 50.9%
Total euthyroid 549 2392
Euthyroid stroke cases 23 131
Total SCH 31 338
SCH stroke cases 1 22
HR [95% CI] 0.77 [0.10, 5.50] 1.37 [0.62, 2.07]
Total euthyroid, total number of participants with normal thyroid
at baseline; euthyroid stroke cases, total number of euthyroid
participants who developed stroke during study follow-up; total
SCH, total number of participants with SCH at baseline; SCH stroke
cases, number of SCH participants who developed stroke during
study follow-up.
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absent. The European Commission recently funded the
Thyroid Hormone Replacement for Untreated Older Adults
with Subclinical Hypothyroidism Trial (40), which examines
the relationship between thyroid hormone treatment and
several cardiovascular and noncardiovascular outcomes.
Until the results of the trial are published, efficient observa-
tional studies such as ours provide the best available evidence
for clinical or policy decisions.
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